semaglutide weight loss marketing usa & Tirzepatide GLP-1 Campaign – MedSpa Marketing Shop FDA-approved semaglutide drug is the

In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period.

Congratulations to the authorsAmalie Dyrelund Broks, Mads Brner Kristensen,Bolette Hartmann,Knud Josefsen,Jens Juul Holst, and Tue Kragstrupfor theirwork - and forhelping chartexciting new research avenues and novel treatment approaches for patients. You canfindthe paper, Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthriti, here: #GLP1 #Rheumatology #Arthritis #TranslationalResearch #ClinicalResearch #Inflammation

With the data we have so far, GLP-1 receptor agonists really are blockbuster drugs

Rahul Gopal #Pharmacovigilance #AdverseDrugReaction #ADRReporting #Semaglutide #GLP1ReceptorAgonist #PatientSafety #ClinicalPharmacy #PharmacyStudents #ClinicalResearch #DrugSafety #PvPI #IPC #HealthcareIndia #MEDCLINIGEN #DrRahulGopal

Find out more with Omada.

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management